Nitrogen In R Patents (Class 514/626)
-
Publication number: 20120294907Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: August 6, 2012Publication date: November 22, 2012Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20120294926Abstract: The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20120282242Abstract: Methods for treating ocular and periocular disorders by administration to a human patient of a therapeutically effective amount of a compound that modulates muscle action.Type: ApplicationFiled: July 20, 2012Publication date: November 8, 2012Inventor: Marcio Marc ABREU
-
Publication number: 20120283233Abstract: The present invention relates to a carrier composition comprising a phosphate compound of an electron transfer agent and a polar aprotic solvent. Biologically active compounds formulated with the carrier composition have been shown to have improved properties.Type: ApplicationFiled: February 4, 2011Publication date: November 8, 2012Inventors: Paul David Gavin, Mahmoud El-Tamimy, Roksan Libinaki, Mohammad Reza Mozafari
-
Publication number: 20120276017Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.Type: ApplicationFiled: March 23, 2012Publication date: November 1, 2012Inventors: David Lickrish, Feng Zhang
-
Publication number: 20120277256Abstract: Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.Type: ApplicationFiled: July 5, 2012Publication date: November 1, 2012Applicant: Synthonics, Inc.Inventors: Thomas Piccariello, Scott B. Palmer, John D. Price, Robert Oberlender, Mary C. Spencer, Michaela E. Mulhare
-
Publication number: 20120277156Abstract: Described are methods of inhibiting heterotopic ossification (HO) in a subject in need thereof. The methods involve administering an effective amount of a proprioception inhibitor to the subject, whereby HO is inhibited or prevented. The present invention also relates to a method of treating a subject with bone trauma. This involves administering a proprioception inhibitor to the subject under conditions effective to treat the bone trauma, where the proprioception inhibitor prevents or inhibits HO.Type: ApplicationFiled: July 21, 2010Publication date: November 1, 2012Applicant: UNIVERSITY OF WASHINGTON TRHOUGH IT'S CENTER FOR COMMERCIALIZATIONInventors: Ted Gross, Steve Bain, Sean Nork
-
Publication number: 20120252733Abstract: Provided herein are compositions and related methods useful for accelerating bone healing and growth. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity.Type: ApplicationFiled: June 4, 2010Publication date: October 4, 2012Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Michael W. Epperly, Abhay Sudhir Gokhale, Joel S. Greenberger, Peter Wipf, Julianne Glowacki
-
Publication number: 20120248142Abstract: A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.Type: ApplicationFiled: November 10, 2010Publication date: October 4, 2012Applicant: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Adrian Francis Davis
-
Publication number: 20120238624Abstract: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.Type: ApplicationFiled: September 14, 2011Publication date: September 20, 2012Inventor: Manoj Maniar
-
Publication number: 20120232111Abstract: The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin—inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent comprises one or more compounds selected from the group consisting of ?-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of ?-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent.Type: ApplicationFiled: April 28, 2006Publication date: September 13, 2012Applicant: Shiseido Company, Ltd.Inventors: Mikiko Kaminuma, Masaru Suetsugu, Toshii Iida, Shinji Inomata
-
Patent number: 8263660Abstract: The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15° C. -27° C.). The present invention also concerns a method for manufacturing said compositions.Type: GrantFiled: February 14, 2007Date of Patent: September 11, 2012Assignee: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati
-
Publication number: 20120226245Abstract: Disclosed is a transdermally absorbable preparation, in which an adhesive agent produced by crosslinking at least one copolymer is contained in an adhesive layer and the aging period in the production of the adhesive layer can be shortened. The transdermally absorbable preparation comprises a support and an adhesive layer arranged on the support and containing an adhesive agent and a medicinal component. The transdermally absorbable preparation is characterized in that the adhesive agent comprises a resin mixture comprising 100 parts by mass of a specific acrylic copolymer (A) and 0.1 to 30 parts by mass of a specific acrylic copolymer (B) or 0.05 to 2 part(s) by mass of a polyamine compound, and the adhesive layer additionally contains an organic acid.Type: ApplicationFiled: September 1, 2010Publication date: September 6, 2012Applicant: NIPRO PATCH CO., LTD.Inventors: Naohisa Kawamura, Chie Sugaya
-
Publication number: 20120213869Abstract: A pain relieving composition that includes an anesthetic in the range of 0.5%-7.0% by weight (“w/w”), an anti-inflammatory agent in the range of 1.0%-11.0% w/w, a moisturizing agent in the range of 0.5%-12.0% w/w, a humescent in the range of 0.5%-13.0% w/w, a penetration enhancing agent in the range of 0.5%-7.0%, and a carrier solvent in the range of 40.0%-97.0% w/w to be used before and/or after procedures which cause damage to human skin.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: MISS SMARTY PANTS ENTERPRISES, INC.Inventor: Edna Ma
-
Publication number: 20120214874Abstract: In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient; an ester; a non-ionic surfactant; a polar solvent; water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster.Type: ApplicationFiled: August 26, 2010Publication date: August 23, 2012Applicant: Nuvo Research Inc.Inventors: Nadir Buyuktimkin, Servet Buyuktimkin, Jagat Singh, John M. Newsam, Dominic King-Smith, Edward Kisak, Bradley S. Galer, Tejas Desai, Christopher Riley
-
Publication number: 20120208890Abstract: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.Type: ApplicationFiled: January 13, 2012Publication date: August 16, 2012Applicant: ALLERGAN, INC.Inventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost, Sumit Paliwal, Dennis Van Epps
-
Patent number: 8241660Abstract: This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel.Type: GrantFiled: August 20, 2007Date of Patent: August 14, 2012Inventor: Martin Wenckens
-
Publication number: 20120201891Abstract: A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.Type: ApplicationFiled: March 30, 2011Publication date: August 9, 2012Inventors: Jeremy Cottrell, Giacinto Gaetano, Mahmoud El-Tamimy, Nicholas Kennedy, Paul David Gavin
-
Publication number: 20120202780Abstract: A carrier composition of the present invention comprises a phosphate compound of an electron transfer agent and a relatively high concentration of a polar protic solvent. A biologically active compound may be formulated with a carrier composition of the present invention to provide a formulation.Type: ApplicationFiled: December 22, 2010Publication date: August 9, 2012Inventors: Paul David Gavin, Mahmoud El-Tamimy, Jeremy James Cottrell, Giacinto Gaetano, Nicholas John Kennedy
-
Publication number: 20120196933Abstract: The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.Type: ApplicationFiled: December 22, 2011Publication date: August 2, 2012Inventors: Richard Franklin, Bernard T. Golding, Robert G. Tyson
-
Publication number: 20120191068Abstract: Method are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period.Type: ApplicationFiled: January 10, 2012Publication date: July 26, 2012Applicant: TARIS BIOMEDICAL, INC.Inventors: Julie Himes, Dennis Geising, Cheryl Larrivee-Elkins, Michael J. Cima, Purnanand Sarma, Paul Goldenheim
-
Publication number: 20120190671Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: March 20, 2012Publication date: July 26, 2012Applicants: The Regents of the University of California, Otonomy, Inc.Inventors: Jay Lichter, Benedikt Vollrath, Sergio G. Duron, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Andrew M. Trammel, Michael Christopher Scaife, Jeffrey P. Harris
-
Publication number: 20120172363Abstract: The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). The present invention further relates to a method for preventing damage and death in mammalian organs, tissues and cells or reducing the extent of damage and death in mammalian organs, tissues and cells. In particular the invention relates to a method for the treatment, amelioration or prevention of non-neuronal and non-myocardial cell or tissue damage or death and for reducing the pain associated with non-neuronal and non-myocardial cell or tissue damage.Type: ApplicationFiled: June 29, 2010Publication date: July 5, 2012Applicant: Ozleo Pty LtdInventors: Paul Nathaniel Smith, Steven Michael Weiss
-
Publication number: 20120172429Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.Type: ApplicationFiled: July 9, 2010Publication date: July 5, 2012Inventors: Clifford J. Woolf, Bruce P. Bean
-
Publication number: 20120172392Abstract: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.Type: ApplicationFiled: March 7, 2012Publication date: July 5, 2012Inventors: LUISA M. SALTER-CID, ERIC Y. WANG, MARY T. MACDONALD, JINGJING ZHAO
-
Patent number: 8202893Abstract: One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and/or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.Type: GrantFiled: October 12, 2005Date of Patent: June 19, 2012Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Chen Li, Dai Lu
-
Publication number: 20120149779Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Inventors: James N. Campbell, Arthur F. Michaelis
-
Patent number: 8193238Abstract: The present invention generally concerns microtubule protrusions in cancer cells, including detached cancer cells, and inhibition of the protrusions. In particular aspects, the inhibition of the protrusions interferes with attachment of the cell to a vessel wall, and in further aspects the cell is killed by forcing it to enter capillaries and be destroyed, for example by shearing. Inhibition by a variety of agents and methods is contemplated.Type: GrantFiled: March 8, 2007Date of Patent: June 5, 2012Assignee: University of Maryland, BaltimoreInventors: Stuart Martin, Rebecca Whipple-Bettes
-
Publication number: 20120129860Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: January 27, 2012Publication date: May 24, 2012Applicant: Acucela, Inc.Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Anna Gall, Mark W. Orme, Jennifer Gage, Thomas L. Little, JR., Qin Jiang, Lana Michele Rossiter, Kevin F. McGee, JR., Ryo Kubota
-
Patent number: 8182464Abstract: Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is configured for minimally invasive insertion into a body cavity, such as the bladder. The hollow tube may be elastomeric to permit the device to be elastically deformed from its initial shape into an elongated shape for passage through a catheter, where following such passage the device can return to or toward its initial shape to facilitate retention of the device in the body cavity. The body may have a narrow, elongated shape effective to permit insertion of the drug delivery device through a catheter without necessarily deforming the body, yet include flexible projections which effect retention within the body cavity.Type: GrantFiled: February 22, 2010Date of Patent: May 22, 2012Assignees: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Heejin Lee, Karen Danielle Daniel, Hong Linh Ho Duc, Michael J. Cima, Mario Castillo, Steven Froelich, Jordan Dimitrakov, Grace Y. Kim
-
Publication number: 20120115950Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: December 28, 2011Publication date: May 10, 2012Applicant: SHIRE LLCInventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
-
Publication number: 20120095386Abstract: Device structure 100 for iontophoresis provides electrode 101 and electrically conductive layer 102. Electrically conductive layer 102 contains active ingredient D and basic water swelling methacrylate copolymer P1 and/or acidic water swelling methacrylate copolymer P2. Electrode 101 and electrically conductive layer 102 are placed into a hollow of backing 103 and electrode terminal 104 is connected to electrode 101 through backing 103. Adhesive layer 105 is set around backing 103, and liner 106 to be removed when using the device, is placed so as to cover the hollow of backing 103.Type: ApplicationFiled: October 1, 2010Publication date: April 19, 2012Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Hirotoshi Adachi, Noriyuki Kuzumaki, Tetsuya Arimoto, Naruhito Higo
-
Publication number: 20120095104Abstract: There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed.Type: ApplicationFiled: May 30, 2011Publication date: April 19, 2012Inventor: Oron ZACHAR
-
Patent number: 8158613Abstract: In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35° C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes.Type: GrantFiled: July 8, 2010Date of Patent: April 17, 2012Assignee: PharmaKodex LimitedInventors: John Nicholas Staniforth, Michael John Tobyn
-
Patent number: 8148359Abstract: The present invention relates to compounds that can be used as metal-ion-chelating agents or as depolluting agents, corresponding to general formula (I) below: and also to precursor compounds of formula (II) and labelled compounds of formula (III) deriving from the compounds of formula (I). The present invention also relates to the use of the compounds (I), (II) or (III) as a medicament, and also the use thereof for the diagnosis, prevention and treatment of neurodegenerative diseases such as Wilson's disease and Alzheimer's disease.Type: GrantFiled: March 13, 2009Date of Patent: April 3, 2012Assignee: Commissariat a l'Energie AtomiqueInventors: Pascale Delangle, Christelle Gateau, Anaïs Pujol
-
Publication number: 20120077822Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.Type: ApplicationFiled: January 29, 2011Publication date: March 29, 2012Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
-
Patent number: 8138374Abstract: The present invention provides a composition for external application to skin containing one type or two or more types of compounds selected from the group consisting of aminoacetoamide compounds represented by the following general formula (1) and salts thereof.Type: GrantFiled: January 24, 2008Date of Patent: March 20, 2012Assignee: Shiseido Company, Ltd.Inventors: Mikiko Kaminuma, Masaru Suetsugu, Nobuhiko Ochiai, Makoto Tsunenaga
-
Publication number: 20120046272Abstract: The present invention describes a series of therapeutically active compounds of formula I, X—Y—Z??(I) that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH2)n—, —CO—, —CONRa—, —NRaCO—, —NRaCOO—, —COO—, —CONRaCO—, —CONRaCOO— and —COOCOO—.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Applicant: GRUNENTHAL GMBHInventor: Ramesh SESHA
-
Patent number: 8119694Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: GrantFiled: August 17, 2009Date of Patent: February 21, 2012Assignee: Arcion Therapeutics, Inc.Inventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20120040019Abstract: This invention relates to an externally applied ointment that aids in relieving irritation, pain or mild inflammation of the skin or mucous membranes associated with hemorrhoids and the method of using such ointment lotion. The formulation of the present invention contains phenylephrine HCl, lidocaine grape skin/seed/leaf extract and aloe plants extract.Type: ApplicationFiled: July 26, 2011Publication date: February 16, 2012Inventors: Archer Rosenblum, John Maurello
-
Patent number: 8114440Abstract: Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.Type: GrantFiled: April 10, 2006Date of Patent: February 14, 2012Assignee: Idexx Laboratories Inc.Inventor: Yerramilli V. S. N. Murthy
-
Publication number: 20120034307Abstract: Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.Type: ApplicationFiled: October 20, 2011Publication date: February 9, 2012Applicant: AKORN, INC.Inventors: Abu Alam, Elias Reichel, Brandon Busbee
-
Publication number: 20120028906Abstract: A method for affecting the timing of cervical ripening and the resultant onset of parturition in a pregnant female mammal, the method comprises administering to a pregnant female one or more than one dose of an agent that chemically mimics innervation of the cervix by the vagus nerve, thereby advancing the onset of parturition, or administering to a pregnant female one or more than one dose of an agent that chemically blocks innervation of the cervix by the vagus nerve, thereby delaying the onset of parturition.Type: ApplicationFiled: March 10, 2010Publication date: February 2, 2012Applicant: LOMA LINDA UNIVERSITYInventor: Steven M. Yellon
-
Publication number: 20120029085Abstract: Compositions and methods are provided for obtaining stabilized quinol compositions, such as catecholamine drugs (e.g., epinephrine solutions), and also for obtaining stable pharmaceutical formulations that comprise a stabilized quinol composition and a second pharmacologically active component such as a local anesthetic or other active drug ingredient having a reversibly protonated amine group. Stability is achieved through the inclusion of an appropriately selected pH buffer and a thiol agent, based on redox and pH buffering principles including pKa of the buffer and of the reversibly protonated amine group.Type: ApplicationFiled: July 29, 2010Publication date: February 2, 2012Inventor: Jon MacKay
-
Publication number: 20120024743Abstract: The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.Type: ApplicationFiled: February 5, 2010Publication date: February 2, 2012Applicant: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulasik, Patrik Fazekas
-
Patent number: 8106080Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: GrantFiled: June 8, 2006Date of Patent: January 31, 2012Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Publication number: 20120021989Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: March 30, 2010Publication date: January 26, 2012Applicant: deCODE Genetics ehf.Inventors: Hilma Holm, Daniel Gudbjartsson
-
Publication number: 20120015901Abstract: The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent.Type: ApplicationFiled: July 13, 2011Publication date: January 19, 2012Applicants: Katholieke Universiteit Leuven, K.U.Leuven R&D, Joanneum Research Forschungsgesellschaft mbH, University of GrazInventors: Joris Winderickx, Greet Van Den Berghe, Jan Gunst, IIse Vanhorebeek, Lies Langouche, Tobias Eisenberg, Frank Madeo, Christophe Magnes, Frank Sinner
-
Publication number: 20110319790Abstract: Provided is a pharmaceutical composition for permeabilizing fetal membranes including an active ingredient having a log K in the range of 2 to 4, where K is the octanol/water partition coefficient. The active ingredient may be, for example, bupivacaine, sodium lauryl sulfate or oleic acid. Further provided is a system for transfetal membrane transport. The system includes a probe unit adapted for insertion into a female reproductive tract and releasing a substance onto fetal membranes that permeabilizes the membranes. The system is also configured to apply ultrasound radiation to the fetal membranes to further increase the membrane permeability.Type: ApplicationFiled: November 25, 2009Publication date: December 29, 2011Applicant: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD.Inventors: Joseph Kost, Mordechai Halak, Drora Shmilovitch, Tamar Triatel, Rivka Goldbart, Aharon Azaguri, Lior Wollach
-
Patent number: RE43327Abstract: The disclosed invention provides new polyamine analogs and derivatives containing a hydrophobic region and a polyamine region as well as methods and compositions for their use.Type: GrantFiled: January 8, 2002Date of Patent: April 24, 2012Assignee: Aminex Therapeutics, Inc.Inventors: Mark R. Burns, Gerard F. Graminski, Nand Baindur